Patents by Inventor Daniel Plaksin

Daniel Plaksin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240327487
    Abstract: Preparations including recombinant FSH (rFSH).
    Type: Application
    Filed: March 14, 2024
    Publication date: October 3, 2024
    Applicant: Ferring International Center S.A.
    Inventors: Ian COTTINGHAM, Daniel PLAKSIN, Richard Boyd WHITE
  • Patent number: 11952407
    Abstract: Preparations including recombinant FSH (rFSH).
    Type: Grant
    Filed: April 30, 2021
    Date of Patent: April 9, 2024
    Assignee: FERRING INTERNATIONAL CENTER S.A.
    Inventors: Ian Cottingham, Daniel Plaksin, Richard Boyd White
  • Publication number: 20220340634
    Abstract: The present disclosure describes recombinant human chorionic gonadotropin (hCG) and methods for the production thereof. The recombinant hCG can include ?2,3, ?2,6, and, optionally, ?2,8 sialylation. The recombinant hCG can be produced in a human cell line such as a PER.C6® cell line.
    Type: Application
    Filed: March 30, 2022
    Publication date: October 27, 2022
    Applicant: Frering B.V.
    Inventors: Ian COTTINGHAM, Daniel PLAKSIN, Rrichard WHITE
  • Publication number: 20220275056
    Abstract: A selective IL-6-trans-signalling inhibitor can be used to treat a variety of IL-6-mediated conditions, including inflammatory diseases and cancer. The inhibitor can safely be administered to humans at a variety of doses.
    Type: Application
    Filed: March 9, 2022
    Publication date: September 1, 2022
    Inventors: Ian Cottingham, Daniel Plaksin, Jérémy Duboeuf
  • Patent number: 11306136
    Abstract: A selective IL-6-trans-signalling inhibitor can be used to treat a variety of IL-6-mediated conditions, including inflammatory diseases and cancer. The inhibitor can safely be administered to humans at a variety of doses.
    Type: Grant
    Filed: November 6, 2019
    Date of Patent: April 19, 2022
    Assignee: Ferring B.V.
    Inventors: Ian Cottingham, Daniel Plaksin, Jérémy Duboeuf
  • Patent number: 11292824
    Abstract: Described are pharmaceutical compositions comprising recombinant human chorionic gonadotropin (hCG) and follicle stimulating hormone (FSH), wherein the recombinant hCG in the composition comprises ?2,3- and ?2,6-sialylation and comprises mono-(1S), di-(2S), tri-(3S) and tetra-(4S) sialylated glycan structures. The recombinant hCG may be obtained by expression in a human cell line, such as the PER.C6 cell line, optionally wherein the cell line is modified using ?2,3-sialyltransferase.
    Type: Grant
    Filed: December 10, 2019
    Date of Patent: April 5, 2022
    Assignee: FERRING B.V.
    Inventors: Ian Cottingham, Daniel Plaksin, Richard White
  • Publication number: 20210332099
    Abstract: Preparations including recombinant FSH (rFSH).
    Type: Application
    Filed: April 30, 2021
    Publication date: October 28, 2021
    Applicant: Ferring International Center SA
    Inventors: Ian COTTINGHAM, Daniel PLAKSIN, Richard Boyd WHITE
  • Patent number: 10995128
    Abstract: Preparations including recombinant FSH (rFSH).
    Type: Grant
    Filed: August 29, 2017
    Date of Patent: May 4, 2021
    Assignee: FERRING INTERNATIONAL CENTER SA
    Inventors: Ian Cottingham, Daniel Plaksin, Richard Boyd White
  • Patent number: 10952959
    Abstract: The subject invention is directed to a pharmaceutical composition comprising an open matrix network incorporating one or more pharmaceutically active ingredients, wherein the open matrix network comprises maltodextrin and hyaluronic acid or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: January 11, 2018
    Date of Patent: March 23, 2021
    Assignee: FERRING B.V.
    Inventors: Ganeshchandra Sonavane, Daniel Plaksin, Varinder Ahuja, Parag Lokhande, Devendra Kantilal Jain
  • Publication number: 20200247863
    Abstract: The present disclosure describes recombinant human chorionic gonadotropin (hCG) and methods for the production thereof. The recombinant hCG can include ?2,3, ?2,6, and, optionally, ?2,8 sialylation. The recombinant hCG can be produced in a human cell line such as a PER.C6® cell line.
    Type: Application
    Filed: December 10, 2019
    Publication date: August 6, 2020
    Applicant: Ferring B.V.
    Inventors: Ian COTTINGHAM, Daniel PLAKSIN, Richard WHITE
  • Publication number: 20200123226
    Abstract: A selective IL-6-trans-signalling inhibitor can be used to treat a variety of IL-6-mediated conditions, including inflammatory diseases and cancer. The inhibitor can safely be administered to humans at a variety of doses.
    Type: Application
    Filed: November 6, 2019
    Publication date: April 23, 2020
    Inventors: Ian Cottingham, Daniel Plaksin, Jérémy Duboeuf
  • Patent number: 10526390
    Abstract: The present disclosure describes recombinant human chorionic gonadotropin (hCG) and methods for the production thereof. The recombinant hCG can include ?2,3, ?2,6, and, optionally, ?2,8 sialylation. The recombinant hCG can be produced in a human cell line such as a PER.C6® cell line.
    Type: Grant
    Filed: May 3, 2017
    Date of Patent: January 7, 2020
    Assignee: FERRING B.V.
    Inventors: Ian Cottingham, Daniel Plaksin, Richard Boyd White
  • Patent number: 10519218
    Abstract: A selective IL-6-trans-signalling inhibitor can be used to treat a variety of IL-6-mediated conditions, including inflammatory diseases and cancer. The inhibitor can safely be administered to humans at a variety of doses.
    Type: Grant
    Filed: December 1, 2015
    Date of Patent: December 31, 2019
    Assignee: FERRING B.V.
    Inventors: Ian Cottingham, Daniel Plaksin, Jérémy Duboeuf
  • Publication number: 20190358156
    Abstract: The subject invention is directed to a pharmaceutical composition comprising an open matrix network incorporating one or more pharmaceutically active ingredients, wherein the open matrix network comprises maltodextrin and hyaluronic acid or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: January 11, 2018
    Publication date: November 28, 2019
    Applicant: Ferring B.V.
    Inventors: Ganeshchandra SONAVANE, Daniel PLAKSIN, Varinder AHUJA, Parag LOKHANDE, Devendra Kantilal JAIN
  • Patent number: 10464984
    Abstract: A host cell characterized in that it comprises integrated into its genome a sequence coding for the a chain of hCG, and use of the host cell to produce recombinant hCG.
    Type: Grant
    Filed: April 22, 2016
    Date of Patent: November 5, 2019
    Assignee: Ferring B.V.
    Inventors: Daniel Plaksin, Ayelet Grinhut
  • Publication number: 20180282396
    Abstract: A selective IL-6-trans-signalling inhibitor can be used to treat a variety of IL-6-mediated conditions, including inflammatory diseases and cancer. The inhibitor can safely be administered to humans at a variety of doses.
    Type: Application
    Filed: December 1, 2015
    Publication date: October 4, 2018
    Applicant: Ferring B.V.
    Inventors: Ian Cottingham, Daniel Plaksin, Jérémy Duboeuf
  • Publication number: 20180079794
    Abstract: Preparations including recombinant FSH (rFSH).
    Type: Application
    Filed: August 29, 2017
    Publication date: March 22, 2018
    Inventors: Ian Cottingham, Daniel Plaksin, Richard Boyd White
  • Publication number: 20180030107
    Abstract: The present disclosure describes recombinant human chorionic gonadotropin (hCG) and methods for the production thereof. The recombinant hCG can include ?2,3, ?2,6, and, optionally, ?2,8 sialylation. The recombinant hCG can be produced in a human cell line such as a PER.C6® cell line.
    Type: Application
    Filed: May 3, 2017
    Publication date: February 1, 2018
    Inventors: Ian Cottingham, Daniel Plaksin, Richard Boyd White
  • Patent number: 9771407
    Abstract: Preparations including recombinant FSH (rFSH).
    Type: Grant
    Filed: August 16, 2016
    Date of Patent: September 26, 2017
    Assignee: Ferring International Center SA
    Inventors: Ian Cottingham, Daniel Plaksin, Richard Boyd White
  • Patent number: 9757469
    Abstract: Polyethylene glycol modified human chorionic gonadotropin (hCG), preparations thereof, compositions thereof, and methods of preparation and use thereof are described.
    Type: Grant
    Filed: March 29, 2012
    Date of Patent: September 12, 2017
    Assignee: Ferring B.V.
    Inventors: Ian Cottingham, Daniel Plaksin, Jenny Aharanov